drugset / Trial / NCT00032045

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

NCT00032045

Open-labelTreatment

Summary

RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining vaccine therapy with a monoclonal antibody may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with monoclonal antibody therapy in treating patients who have stage IV melanoma.

Timeline

Start
2002-01
Primary completion
Completion
2006-08

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody 1 mg/kg Intravenous
Subject Ipilimumab Monoclonal antibody 3 mg/kg Intravenous
Subject gp100 antigen Peptide Subcutaneous
Background incomplete Freund's adjuvant Other / unclassified Subcutaneous